EYP-1901 Shows 9-Month Disease Control in NPDR Patients

Despite missing the 12-month primary endpoint in PAVIA, the implant demonstrated early efficacy, guiding design for a planned phase 3 trial.

By: Jim Gallagher, senior managing editor

Retinal Physician May 8, 2025

Clinical Report: EYP-1901 Shows 9-Month Disease Control in NPDR Patients

Overview

The Phase 2 PAVIA trial of EYP-1901 demonstrated promising disease control in patients with nonproliferative diabetic retinopathy (NPDR) for up to 9 months following a single intravitreal injection. Although the primary endpoint was not met at 12 months, patients maintained stable or improved disease, and the treatment was well tolerated with no new safety concerns.

Background

Nonproliferative diabetic retinopathy (NPDR) is a common complication of diabetes that can lead to vision loss. Current management guidelines emphasize monitoring and treatment only when vision-threatening complications arise. The development of sustained-release therapies like EYP-1901 may provide new options for managing NPDR effectively.

Data Highlights

No numerical data available in the provided source material. Consider including specific findings from the trial.

Key Findings

EYP-1901 is a bioerodible insert delivering vorolanib, a tyrosine kinase inhibitor.
At 6 months, patients showed a statistically significant improvement in DRSS scores compared to sham treatment.
The treatment effect was observed to last approximately 9 months, with effects diminishing by 12 months.
No new safety concerns were reported, reinforcing the favorable safety profile of EYP-1901.
A phase 3 trial is planned to further evaluate the treatment's efficacy and durability.

Clinical Implications

Clinicians should consider the potential of EYP-1901 as a treatment option for NPDR, particularly in patients with moderately severe to severe disease. Ongoing monitoring and adherence to current management guidelines remain essential as further data from larger trials become available.

Conclusion

EYP-1901 shows promise for disease control in NPDR, with a treatment duration of approximately 9 months. Future studies will be crucial to confirm its efficacy and establish its role in clinical practice.

PentaVision

Retinal Physician